-transparent.png){kind=logo}
Fifty consecutive patients with recurrent and metastatic endometrial carcinoma were treated with melphalan, 5-fluorouracil, and medroxyprogesterone acetate with or without tamoxifen as first-line chemotherapy. The objective response rate was 48%, with 20% complete responses. The estimated median progression-free survival time was only five months (0.5 to 65 months) with estimated two- and five-year progression-free survival rates of 16 and 13%, respectively. The estimated median progression-free survival time was 24 months for complete responders; the progression-free survival times were significantly longer than the survival times (median = four months) for all other patients (P = .0002). Whether or not the addition of cytotoxic chemotherapy to progesterone hormonal therapy for metastatic endometrial carcinoma lengthens survival time is still open to question.
M S Piver, and
S B Lele, and
B Patsner, and
L J Emrich
November 1995,
Gynecologic oncology,
M S Piver, and
S B Lele, and
B Patsner, and
L J Emrich
July 1977,
Obstetrics and gynecology,
M S Piver, and
S B Lele, and
B Patsner, and
L J Emrich
October 1977,
Obstetrics and gynecology,
M S Piver, and
S B Lele, and
B Patsner, and
L J Emrich
January 1990,
Gynakologische Rundschau,
M S Piver, and
S B Lele, and
B Patsner, and
L J Emrich
July 1985,
Gynecologic oncology,
M S Piver, and
S B Lele, and
B Patsner, and
L J Emrich
January 1979,
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,
M S Piver, and
S B Lele, and
B Patsner, and
L J Emrich
May 2012,
Oncology letters,
M S Piver, and
S B Lele, and
B Patsner, and
L J Emrich
May 1989,
Zhonghua fu chan ke za zhi,
M S Piver, and
S B Lele, and
B Patsner, and
L J Emrich
June 1981,
American journal of obstetrics and gynecology,
M S Piver, and
S B Lele, and
B Patsner, and
L J Emrich
May 1993,
Gan to kagaku ryoho. Cancer & chemotherapy,
